KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Cost of Revenue: 2016-2025

Historic Cost of Revenue for Sarepta Therapeutics (SRPT) over the last 8 years, with Jun 2025 value amounting to $137.6 million.

  • Sarepta Therapeutics' Cost of Revenue rose 208.82% to $137.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $406.1 million, marking a year-over-year increase of 130.34%. This contributed to the annual value of $319.1 million for FY2024, which is 112.25% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Cost of Revenue stood at $137.6 million for Q2 2025, which was up 3.98% from $132.3 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Cost of Revenue registered a high of $137.6 million during Q2 2025, and its lowest value of $19.5 million during Q2 2021.
  • Over the past 3 years, Sarepta Therapeutics' median Cost of Revenue value was $44.5 million (recorded in 2024), while the average stood at $67.4 million.
  • In the last 5 years, Sarepta Therapeutics' Cost of Revenue decreased by 9.71% in 2023 and then skyrocketed by 208.82% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Cost of Revenue (Quarterly) stood at $31.7 million in 2021, then declined by 2.98% to $30.8 million in 2022, then surged by 43.43% to $44.2 million in 2023, then skyrocketed by 199.49% to $132.3 million in 2024, then skyrocketed by 208.82% to $137.6 million in 2025.
  • Its Cost of Revenue stands at $137.6 million for Q2 2025, versus $132.3 million for Q4 2024 and $91.7 million for Q3 2024.